Loading company…
PepGen develops therapeutics for genetic neuromuscular and neurological diseases.
Founded in 2018 and based in Cambridge, US, PepGen develops disease-modifying therapies for genetic neuromuscular and neurological diseases, including muscular dystrophies and spinal muscular atrophy. Its programs include the PGN-EDODM1 molecule and are being evaluated in clinical trials. The company has raised USD 108.00 mn across six deals, with its latest funding round an IPO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in